Hexvix (Hexaminolevulinate)

Hexvix is indicated for the photodynamic diagnosis of bladder cancer during cystoscopic evaluation.

• Detection of carcinoma in situ (CIS) of the bladder.
• Identification of papillary urothelial tumors (Ta, T1).
• Adjunct to white‑light cystoscopy to improve lesion visibility.
• Guidance for biopsy targeting and resection planning.
• Assessment of tumor recurrence after prior treatment.
• Differentiation between inflammatory changes and malignant lesions during surveillance.
• Use in patients undergoing initial diagnosis or follow‑up after intravesical therapy.

• Hexvix contains hexyl aminolevulinate, a prodrug that enters urothelial cells and is metabolized in the heme biosynthetic pathway to protoporphyrin IX. Malignant cells have increased activity of porphobilinogen deaminase, leading to selective accumulation of protoporphyrin IX. When illuminated with blue light (380–450 nm), the accumulated porphyrin emits red fluorescence, allowing visual discrimination of cancerous tissue from normal bladder mucosa. The fluorescence persists for several hours, providing a practical window for cystoscopic inspection.

Adverse reactions reported with intravesical Hexvix are generally related to the local application and to the photodynamic process.

Common

• Transient bladder irritation or burning sensation during or after instillation.
• Mild hematuria or pink urine discoloration.
• Dysuria or increased urinary frequency.
• Low‑grade fever or chills lasting less than 24 hours.
• Mild suprapubic discomfort.
• Temporary increase in urinary urgency.

Serious

• Acute allergic reaction with rash, pruritus, or angioedema.
• Severe bladder spasm or painful urinary retention.
• Persistent hematuria requiring medical intervention.
• Photosensitivity of the bladder mucosa leading to ulceration.
• Systemic hypersensitivity reaction (anaphylaxis).
• Significant renal impairment due to obstruction.

Most events are mild, self‑limiting, and resolve without specific treatment, but clinicians should monitor patients for any escalation.

Before using Hexvix, clinicians should evaluate patient history and bladder condition to minimize risks associated with the photodynamic procedure.

• Ensure no active urinary tract infection; treat infection prior to instillation.
• Verify that the bladder is free of gross blood or large clots.
• Contraindicated in patients with known hypersensitivity to hexyl aminolevulinate or porphyrin compounds.
• Use caution in patients with severe renal impairment or urinary retention.
• Avoid use during pregnancy or lactation due to unknown fetal risk.

Hexvix may interact with other agents administered intravesically or systemically; awareness of potential interactions helps prevent reduced diagnostic accuracy or increased toxicity.

Avoid

• Concurrent use of other photosensitizing drugs (e.g., porfimer sodium) during the same cystoscopic session.
• Simultaneous intravesical chemotherapy or immunotherapy agents, which may alter fluorescence or cause additive irritation.

Use with caution

• Systemic antibiotics that cause urinary discoloration, potentially interfering with visual assessment.
• Anticoagulants, as they may increase the risk of hematuria after instillation.
• Agents that affect bladder contractility (e.g., anticholinergics), which could modify drug distribution.